Compare H2O America (HTO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs TG Therapeutics Inc — how do they compare? H2O America trades at $63.79 (market cap $2.70B), while TG Therapeutics Inc trades at $54.06 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 3.1× H2O America's market cap, and H2O America pays a 2.73% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HTO | TGTX | |
|---|---|---|
Market Cap | $2.70B | $8.26B |
Sector | Technology | Health |
52-Week High | $65.43 | $59.06 |
52-Week Low | $44.44 | $26.39 |
Enterprise Value | $4.42B | $8.50B |
Dividend Yield | 2.73% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
